PF 4531083Alternative Names: PF-04531083
Latest Information Update: 14 Aug 2012
At a glance
- Originator Pfizer
- Class Analgesics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain; Postoperative pain
Most Recent Events
- 10 Jul 2012 Pfizer terminates phase II trial in Postoperative pain in USA (NCT01512160)
- 22 May 2012 Pfizer completes enrolment in its phase II trial for Postoperative pain in USA (NCT01512160)
- 10 May 2012 Discontinued - Phase-I for Pain in Belgium (PO)